LONDON, Feb. 12, 2018 -- Today, Citeline, part of Informa Pharma Intelligence’s suite of pharmaceutical, medtech and biomedical research and analysis solutions, and Saama Technologies, Inc., a leading clinical analytics company, announced a partnership to integrate Citeline’s application programming interfaces (APIs) with Saama’s artificial intelligence and deep learning solutions.
This is a strategic effort to bridge global clinical data and real-world data to improve both planning for and conducting clinical trials. Joint customers will get unparalleled insight into robust clinical trial intelligence with greater efficiency than before.
Saama is integrating with Citeline’s APIs, including Trialtrove and Sitetrove, which provide users with the ability to go even deeper with search criteria and make better, more well-informed decisions, gain competitive advantage, and optimize ROI for their clinical trials. Combined with Saama’s real-world analytics, mutual customers will have smarter, more streamlined and successful clinical trials.
“This partnership represents a great use case for Citeline’s newly released API’s,” said Jason Tse, Head of Strategic Partnerships at Informa Pharma Intelligence. "We’re continuing to drive innovative products alongside our partners and bridge real-world data with our clinical trial information, tackling a growing unmet need in our industry. Through this partnership, our joint customers will be able to overcome clinical development challenges, gain industry insights, and optimize trial success through multiple points of triangulation.”
“The partnership between Citeline’s expert clinical trial data and Saama’s award-winning AI-enabled technologies, which leverage both structured and unstructured real-world data, represents the next phase of intelligent clinical trial planning and execution,” said Luke Stewart, Director of Product Management at Saama.
Attendees at this week’s 2018 Summit for Clinical Ops Executives (SCOPE) meeting in Orlando should visit Informa Pharma Intelligence at booth 617 and Saama at booth 316 to learn more about the partnership.
About Informa Pharma Intelligence
Informa Pharma Intelligence powers a full suite of analysis products - Datamonitor Healthcare, Sitetrove, Trialtrove, Pharmaprojects, Medtrack, Biomedtracker, Scrip, Pink Sheet and In Vivo – to deliver the data needed by the pharmaceutical and biomedical industry to make decisions and create real-world opportunities for growth.
With more than 500 analysts keeping their fingers on the pulse of the industry, no key disease, clinical trial, drug approval or R&D project isn’t covered through the breadth and depth of data available to customers. For more information visit pharmaintelligence.informa.com.
About Citeline
Citeline, part of Informa’s Pharma Intelligence vertical, is the world’s most comprehensive source of real-time R&D intelligence for the pharmaceutical industry, featuring an unmatched intelligence collection and enrichment of global clinical trials, clinical trial investigator profiles and drug development pipelines.
Citeline is the R&D Intelligence arm of Informa’s Pharma Intelligence vertical, one of the world’s leading providers of drug, device, company, clinical trial and market intelligence in the pharma and medtech markets. For more information, visit pharmaintelligence.informa.com.
About Saama
Saama Technologies is the advanced data and analytics company delivering actionable business insights for life sciences and the Global 2000. We are singularly focused on driving fast, flexible, impactful business outcomes for our clients through data and analytics. Our unique “hybrid” approach integrates focused solutions and expertise across the life sciences domain, business consulting, data science, automated data management, and big data technologies. We integrate manual and disconnected initiatives into a well-aligned roadmap facilitating the client’s journey from strategy through solution implementation.
Media Contact
Diffusion PR for Informa Pharma Intelligence
Allie Tedone
[email protected]
646.571.0120


Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
Instagram Outage Disrupts Thousands of U.S. Users
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Ford and Geely Explore Strategic Manufacturing Partnership in Europe
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 



